MorphoSys AG (MOR) 2022年年度报告「NASDAQ」.pdf

1、Annual Report2022Our Clinical PipelineMost advanced development stageProgramIndicationTafasitamab1L-MIND/Relapsed or refractory(r/r)diffuse large B-cell lymphoma(DLBCL)l l2lfrontMIND/First-line DLBCLl l linMIND/r/r follicular lymphoma/marginal zone lymphomal l lB-MIND/r/r DLBCLl l lfirstMIND/First-l

2、ine DLBCLl PelabresibMANIFEST-2/Myelofibrosisl l lMANIFEST/Myelofibrosis/essential thrombocythemia l lTulmimetostat(CPI-0209)Advanced solid tumors/hematologic malignanciesl l1 Global collaboration and license agreement with Incyte Corporation;co-commercialization in the U.S.;Incyte has exclusive com

3、mercialization rights outside the U.S.2 Not conducted,as not necessary.MorphoSys,March 2023Clinical Programs Developed by Partners(Selection)Most advanced development stageProgram/Partner(s)IndicationIanalumab(VAY736)/NovartisAutoimmune diseasesl l lAbelacimab(MAA868)/Anthos TherapeuticsAssociated t

4、hrombosisl l lSetrusumab(BPS804)/Mereo/UltragenyxOsteogenesis imperfectal lFelzartamab/I-Mab/HI-Bior/r multiple myeloma 1l l lIGNAZ2/Immunoglobulin A nephropathyl lM-PLACE2/Anti-PLA2R-positivemembranous nephropathyl New-PLACE2/Anti-PLA2R-positive membranous nephropathyl lNOV-8(CMK389)/NovartisPulmon

5、ary sarcoidosisl lBimagrumab/Versanis BioObesityl lNOV-9(LKA651)/NovartisDiabetic eye diseasesl lMOR2103/I-Mab/HI-Bior/r advanced solid tumorsl 1 I-Mab Biopharma holds the exclusive regional rights to develop and commercialize felzartamab in Greater China.2 HI-Bio obtained exclusive rights to develo

6、p and commercialize felzartamab across all indications worldwide,with the exception of Greater China.3 HI-Bio obtained exclusive worldwide rights to develop and commercialize MOR210 across all indications worldwide,with the exception of Greater China and South Korea.I-Mab Biopharma holds the exclusi